How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI

In September 2026, Ultragenyx Pharmaceutical received full U.S. FDA approval for FAYUVI (UX111), the first-ever treatment for pediatric patients with Sanfilippo syndrome Type A, along with a Priority Review Voucher. This approval not only addresses a previously untreated ultra-rare, fatal neurodegenerative disease but also expands Ultragenyx's commercial gene therapy portfolio and manufacturing footprint in the U.S. We'll now explore how FAYUVI's first-in-disease approval and the associated Priority Review Voucher affect Ultragenyx's existing investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft.